People · Operator
Named in public records as an officer, director or promoter · active 2022–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Access Vascular, Inc. | — | Biotechnology | Series B | $61.8M | $200.4M | 2022 |
Brent Sabin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brent Sabin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| JJ Pelligrino | 1 | 1 |
| Amine R Bentaleb | 1 | 1 |
| James Biggins | 1 | 1 |
| Luc R Marengere | 1 | 1 |
| Michael R Jaff | 1 | 1 |
| Marc R Riviere | 1 | 1 |
| Paul Sabin | 1 | 1 |
| Brent Ratz | 1 | 1 |
| Alexandra R MacLean | 1 | 1 |
| Joseph Pellegrino | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.